Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Giusy Cetani, Mario Boccadoro & Stefania Oliva. (2018) A look at treatment strategies for relapsed multiple myeloma. Expert Review of Anticancer Therapy 18:8, pages 735-750.
Read now
Read now
Max J. Gordon, Lionel D. Lewis, Jennifer R. Brown & Alexey V. Danilov. (2017) Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities – is there an optimal dose?. Expert Review of Hematology 10:8, pages 707-718.
Read now
Read now
Samantha Pozzi, Massimo Gentile, Stefano Sacchi, Raffaella Marcheselli, Alessandro Corso, Federica Cocito, Pellegrino Musto, Attilio Guarini, Carla Minoia, Iolanda Vincelli, Roberto Ria, Elena Rivolti, Giuseppe Mele, Alessia Bari, Carla Mazzone, Stefania Badiali, Luigi Marcheselli, Antonio Palumbo & Fortunato Morabito. (2017) Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. Leukemia & Lymphoma 58:3, pages 552-559.
Read now
Read now
Fabiana Gentilini, Gregorio Brunetti, Paola Finsinger, Marta Chisini, Claudio Cartoni, Robin Foà & Maria Teresa Petrucci. (2016) Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program. Leukemia & Lymphoma 57:7, pages 1716-1718.
Read now
Read now
Bruce D. Cheson, Wolfram Brugger, Gandhi Damaj, Martin Dreyling, Brad Kahl, Eva Kimby, Michinori Ogura, Eckhart Weidmann, Clemens-Martin Wendtner & Pier Luigi Zinzani. (2016) Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. Leukemia & Lymphoma 57:4, pages 766-782.
Read now
Read now
Pellegrino Musto, Vincenzo Ludovico Fraticelli, Giovanna Mansueto, Emanuela Madonna, Andrea Nozza, Alessandro Andriani, Alberto Mussetti, Stelvio Ballanti, Velia Bongarzoni, Anna Baraldi, Francesca Patriarca, Donatella Vincelli, Antonietta Falcone, Daniele Derudas, Catello Califano, Renato Zambello, Giuseppe Mele, Alberto Fragasso, Luca Baldini & Sergio Storti. (2015) Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon. Leukemia & Lymphoma 56:5, pages 1510-1513.
Read now
Read now
Antonio Palumbo, Massimo Offidani, Francesca Patriarca, Maria Teresa Petrucci & Michele Cavo. (2015) Bendamustine for the treatment of multiple myeloma in first-line and relapsed–refractory settings: a review of clinical trial data. Leukemia & Lymphoma 56:3, pages 559-567.
Read now
Read now
Sylvanie Surget, Emilie Lemieux-Blanchard, Sophie Maïga, Géraldine Descamps, Steven Le Gouill, Philippe Moreau, Martine Amiot & Catherine Pellat-Deceunynck. (2014) Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leukemia & Lymphoma 55:9, pages 2165-2173.
Read now
Read now
Massimo Gentile, Anna Grazia Recchia, Carla Mazzone, Ernesto Vigna, Massimo Martino, Lucio Morabito, Eugenio Lucia, Sabrina Bossio, Laura De Stefano, Teresa Granata, Angela Palummo & Fortunato Morabito. (2013) An old drug with a new future: bendamustine in multiple myeloma. Expert Opinion on Pharmacotherapy 14:16, pages 2263-2280.
Read now
Read now
Anna Korycka-Wołowiec & Tadeusz Robak. (2012) Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1455-1468.
Read now
Read now
Articles from other publishers (28)
Bruno Almeida Costa, Tarek H. Mouhieddine, Ricardo J. Ortiz & Joshua Richter. (2023) Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives. Critical Reviews in Oncology/Hematology 187, pages 104040.
Crossref
Crossref
Sudhir Kumar, Atul Sharma, Prabhat Singh Malik, Ajay Gogia, Neha Pathak, Ranjit Kumar Sahoo, Ritu Gupta, Chandra Prakash Prasad & Lalit Kumar. (2022) Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial. British Journal of Haematology 198:2, pages 288-297.
Crossref
Crossref
Norbert Grzasko, Grzegorz Charlinski, Marta Morawska, Pawel Kicinski, Anna Waszczuk-Gajda, Joanna Drozd-Sokolowska, Edyta Subocz, Danuta Blonska, Malgorzata Razny, Agnieszka Druzd-Sitek, Jadwiga Holojda, Alina Swiderska, Lidia Usnarska-Zubkiewicz, Anna Masternak & Krzysztof Giannopoulos. (2021) Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. Journal of Clinical Medicine 10:23, pages 5504.
Crossref
Crossref
Jasmine M. Zain & Paul Hanona. (2021) Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management. American Journal of Hematology 96:8, pages 1027-1046.
Crossref
Crossref
Anne-Claire Mamez, Axelle Dupont, Didier Blaise, Patrice Chevallier, Edouard Forcade, Patrice Ceballos, Mohamad Mohty, Felipe Suarez, Yves Beguin, Regis Peffault De Latour, Marie-Thérèse Rubio, Olivier Tournilhac & Stéphanie Nguyen. (2020) Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Journal of Hematology & Oncology 13:1.
Crossref
Crossref
Romana Ryšavá. (2019) AL amyloidosis: advances in diagnostics and treatment. Nephrology Dialysis Transplantation 34:9, pages 1460-1466.
Crossref
Crossref
Seung-Shin LeeJe-Jung Lee. (2019) Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma. Chonnam Medical Journal 55:1, pages 25.
Crossref
Crossref
G Damaj, J Cornillon, K Bouabdallah, R Gressin, S Vigouroux, T Gastinne, F Ranchon, H Ghésquières, G Salles, I Yakoub-Agha & E Gyan. (2017) Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. Bone Marrow Transplantation 52:7, pages 941-949.
Crossref
Crossref
Pieter Sonneveld, Edwin De Wit & Philippe Moreau. (2017) How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. Critical Reviews in Oncology/Hematology 112, pages 153-170.
Crossref
Crossref
Iris Breitkreutz, Natalia Becker, Axel. Benner, Florentina Kosely, Christoph Heining, Jens Hillengass, Gerlinde Egerer, Anthony D. Ho, Hartmut Goldschmidt & Marc S. Raab. (2016) Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematological Oncology 34:4, pages 200-207.
Crossref
Crossref
D J Green, W I Bensinger, L A Holmberg, T Gooley, B G Till, L E Budde, J M Pagel, S L Frayo, J E Roden, L Hedin, O W Press & A K Gopal. (2016) Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. Bone Marrow Transplantation 51:10, pages 1330-1336.
Crossref
Crossref
Francisco Javier Peñalver, Julio Delgado, Javier Loscertales, Jose Luis Sastre, Asunción Peña, María Teresa Olave, Santiago Osorio, Adolfo de la Fuente, Antonio Salar, Carlos Grande, Elena Pérez Ceballos, Guillermo Debén, Asunción Echeveste, Felipe Casado, Javier de la Rubia, Juan José Lahuerta & María Victoria Mateos. (2016) Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. European Journal of Haematology 96:5, pages 532-540.
Crossref
Crossref
J Laubach, L Garderet, A Mahindra, G Gahrton, J Caers, O Sezer, P Voorhees, X Leleu, H E Johnsen, M Streetly, A Jurczyszyn, H Ludwig, U-H Mellqvist, W-J Chng, L Pilarski, H Einsele, J Hou, I Turesson, E Zamagni, C S Chim, A Mazumder, J Westin, J Lu, T Reiman, S Kristinsson, D Joshua, M Roussel, P O'Gorman, E Terpos, P McCarthy, M Dimopoulos, P Moreau, R Z Orlowski, J S Miguel, K C Anderson, A Palumbo, S Kumar, V Rajkumar, B Durie & P G Richardson. (2015) Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30:5, pages 1005-1017.
Crossref
Crossref
Seok Jin KimSoo-Mee BangYoon Seok ChoiDeog-Yeon JoJin Seok KimHyewon LeeHyeon Seok EomDok Hyun YoonCheolwon SuhJe-Jung LeeJunshik HongJae Hoon LeeYoungil KohKihyun KimSung-Soo YoonChang-Ki Min. (2016) Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Blood Research 51:3, pages 193.
Crossref
Crossref
Claudio Cerchione, Davide Nappi, Maria Di Perna, Irene Zacheo, Anna Emanuele Pareto, Marco Picardi, Lucio Catalano & Fabrizio Pane. (2016) Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma. Case Reports in Hematology 2016, pages 1-3.
Crossref
Crossref
Shaji K Kumar, Amrita Krishnan, Betsy LaPlant, Kristina Laumann, Vivek Roy, Todd Zimmerman, Morie A Gertz, Francis K Buadi, Keith Stockerl Goldstein, Ann Birgin, Mark Fiala, Lupe Duarte, Michelle Maharaj, Joan Levy & Ravi Vij. (2015) Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology 90:12, pages 1106-1110.
Crossref
Crossref
Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lucio Morabito, Francesco Mendicino, Giovanna Giagnuolo & Fortunato Morabito. (2015) Bendamustine in multiple myeloma. European Journal of Haematology 95:5, pages 377-388.
Crossref
Crossref
Steve Schey, Sarah R. Brown, Avie-Lee Tillotson, Kwee Yong, Cathy Williams, Faith Davies, Gareth Morgan, Jamie Cavenagh, Gordon Cook, Mark Cook, Guillermo Orti, Curly Morris, Debbie Sherratt, Louise Flanagan, Walter Gregory & James Cavet. (2015)
Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUK
one
randomized dose selection trial
. British Journal of Haematology 170:3, pages 336-348.
Crossref
Crossref
C S Chim & K Y Wong. (2014) Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation. Bone Marrow Transplantation 49:12, pages 1545-1547.
Crossref
Crossref
G. Pratt, S. Bowcock, M. Lai, S. Bell, J. Bird, S. D'Sa, J. Cavenagh, G. Cook, G. Morgan, R. Owen, J.A. Snowden, K. Yong & F. Davies. (2014) United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. International Journal of Laboratory Hematology 36:1, pages 20-28.
Crossref
Crossref
Matthew J. Streetly, Jacob Laubach, Paul Richardson & Stephen A. Schey. 2013. Myeloma. Myeloma
144
166
.
M Offidani, L Corvatta, L Maracci, A M Liberati, S Ballanti, I Attolico, P Caraffa, F Alesiani, T Caravita di Toritto, S Gentili, P Tosi, M Brunori, D Derudas, A Ledda, A Gozzetti, C Cellini, L Malerba, A Mele, A Andriani, S Galimberti, P Mondello, S Pulini, U Coppetelli, P Fraticelli, A Olivieri & P Leoni. (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer Journal 3:11, pages e162-e162.
Crossref
Crossref
Mauro Cives, Sabino Ciavarella, Francesca Maria Rizzo, Monica De Matteo, Franco Dammacco & Franco Silvestris. (2013) Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cellular Signalling 25:5, pages 1108-1117.
Crossref
Crossref
Tomer M. Mark, Whitney Reid, Ruben Niesvizky, Usama Gergis, Roger Pearse, Sebastian Mayer, June Greenberg, Morton Coleman, Koen Van Besien & Tsiporah Shore. (2013) A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in?Multiple Myeloma. Biology of Blood and Marrow Transplantation 19:5, pages 831-837.
Crossref
Crossref
Moshe E. Gatt & Giovanni Palladini. (2013) Light chain amyloidosis 2012: a new era. British Journal of Haematology 160:5, pages 582-598.
Crossref
Crossref
Gandhi DamajRémy GressinKrimo BouabdallahGuillaume CartronBachra ChoufiEmmanuel GyanAnne BanosArnaud JaccardSophie ParkOlivier TournilhacJean-Marc Schiano-de CollelaLaurent VoillatBertrand JolySteven Le GouillAlain SaadPascale Cony-MakhoulJean-Pierre VilqueLaurence SanhesAline Schmidt-TanguyMichael BubenheimRoch HouotMomar DioufJean-Pierre MarolleauMarie-Christine BénéAntoine MartinThierry Lamy. (2013) Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial. Journal of Clinical Oncology 31:1, pages 104-110.
Crossref
Crossref
Shahrooz Eshaghian & James R. Berenson. (2012) Multiple myeloma. Current Opinion in Supportive & Palliative Care 6:3, pages 330-336.
Crossref
Crossref
Zhimin Li, Thomas Caulfield, Yushi Qiu, John A. Copland & Han W. Tun. (2012) Pharmacokinetics of bendamustine in the central nervous system: chemoinformatic screening followed by validation in a murine model. MedChemComm 3:12, pages 1526.
Crossref
Crossref